Contact
searchSearch
HMP Global

Who We Are

Editorial Staff

Senior Managing Editor: Coleen M. F. Stern, MA
cstern@hmpglobal.com

Digital Managing Editor: Jessica Garlewicz
jgarlewicz@hmpglobal.com

Associate Editor: Riya Gandhi, MA
rgandhi@hmpglobal.com

Sales Staff

Vice President, Immunology: Jeremy Shapses
jshapses@hmpglobal.com

Associate Director, National Accounts—Dermatology Events: Matthew Brown
mbrown@hmpglobal.com

Business Staff

President & Chief Operating Officer Jeff Hennessy, Jr.
Chief Strategy Officer & Corporate Development Officer Mark Miller
Executive Vice President, Business Development & Product Strategy Kara Rosania

Vice President, Sales Tony Deimler
Director, Market Access Jessica Bell
National Account Manager Sophie Dyer

Executive Vice President, Trade Shows & Conferences Peggy Diab
Senior Creative Director Ashley Thurston-Curry
Senior Director, Production & Audience Development Andrea Steiger

Chairman & Chief Executive Officer Jeff Hennessy
Chief Human Resources Officer Anthony Mancini
Chief Financial Officer Greg Salter
Senior Vice President, Finance & Controller Meredith Cymbor-Jones
Sr. Vice President, Content Development & Operations David DePinho
Vice President, Information Technology Tim Shaw

Digital Operations Staff

Director, Digital Revenue Operations: Katelynn McFadden
Senior Manager, Digital Operations: Addison Fish

Popular Articles

vitiligo
News
Evaluating Efficacy of Ritlecitinib With or Without nbUVB in Treating Non-Segmental Vitiligo
06/28/2024
Riya Gandhi, MA
Ritlecitinib, a JAK3/TEC family kinase inhibitor, has shown promising results in the treatment of non-segmental vitiligo (NSV), according to a recent Phase 2b trial.
Ritlecitinib, a JAK3/TEC family kinase inhibitor, has shown promising results in the treatment of non-segmental vitiligo (NSV), according to a recent Phase 2b trial.
Ritlecitinib, a JAK3/TEC family...
06/28/2024
The Dermatologist
Conference Preview
“One for All:” DNA Annual Convention Preview
09/06/2024
Olanda Hathaway, MSN, FNP-BC, DCNP
The Dermatology Nurses’ Association hosts its 43rd yearly meeting in Orlando, FL, March 5–8, 2025, offering in-person educational and networking opportunities to promote patient care excellence.
The Dermatology Nurses’ Association hosts its 43rd yearly meeting in Orlando, FL, March 5–8, 2025, offering in-person educational and networking opportunities to promote patient care excellence.
The Dermatology Nurses’...
09/06/2024
The Dermatologist
acne
News
Topical Clindamycin: A Safe Choice for Acne Treatment Despite GI Concerns
10/31/2024
Riya Gandhi, MA
A recent review highlighted the safety of topical clindamycin, a popular antibiotic treatment for acne vulgaris.
A recent review highlighted the safety of topical clindamycin, a popular antibiotic treatment for acne vulgaris.
A recent review highlighted the...
10/31/2024
The Dermatologist
Clinical Insights
The Risk of Keratinocyte Cancer in Patients With Vitiligo
08/05/2024
Riya Gandhi, MA
A recent systematic review and meta-analysis offers insights into the relationship between vitiligo and nonmelanoma skin cancer, which can be used to enhance patient education.
A recent systematic review and meta-analysis offers insights into the relationship between vitiligo and nonmelanoma skin cancer, which can be used to enhance patient education.
A recent systematic review and...
08/05/2024
The Dermatologist
atopic dermatitis
FDA Alerts
Lebrikizumab FDA Approved for Moderate to Severe Atopic Dermatitis in Adults and Children
09/16/2024
Jessica Garlewicz
The US Food and Drug Administration has approved Eli Lilly’s EBGLYSS (lebrikizumab-lbkz), an IL-13 inhibitor, for the treatment of moderate to severe atopic dermatitis in adults and children.
The US Food and Drug Administration has approved Eli Lilly’s EBGLYSS (lebrikizumab-lbkz), an IL-13 inhibitor, for the treatment of moderate to severe atopic dermatitis in adults and children.
The US Food and Drug...
09/16/2024
The Dermatologist
June 2026 issue

Current Issue

June 2026
Volume 34
Issue 4
Current Issue
Issue Archive

Latest Quizzes and Trivia

Quiz
Type 2 Endotypes and Therapeutic Strategy in Prurigo Nodularis
06/25/2026
Riya Gandhi, MA
Assess advanced concepts in type 2 inflammatory endotypes, shared therapeutic pathways, and practical treatment approaches in prurigo nodularis.
Assess advanced concepts in type 2 inflammatory endotypes, shared therapeutic pathways, and practical treatment approaches in prurigo nodularis.
Assess advanced concepts in type...
06/25/2026
The Dermatologist
itch
Quiz
Fibrosis and Persistent Itch in Prurigo Nodularis
06/15/2026
Riya Gandhi, MA
Test your clinical understanding of fibrotic remodeling and the mechanisms underlying persistent itch and chronic disease activity in prurigo nodularis.
Test your clinical understanding of fibrotic remodeling and the mechanisms underlying persistent itch and chronic disease activity in prurigo nodularis.
Test your clinical understanding...
06/15/2026
The Dermatologist
brain
Quiz
Neuroimmune Mechanisms and Cytokine Signaling in Prurigo Nodularis
06/05/2026
Riya Gandhi, MA
Explore advanced concepts in neuroimmune communication, cytokine-driven itch amplification, and fibrotic signaling pathways involved in prurigo nodularis.
Explore advanced concepts in neuroimmune communication, cytokine-driven itch amplification, and fibrotic signaling pathways involved in prurigo nodularis.
Explore advanced concepts in...
06/05/2026
The Dermatologist
Quiz
Predicting Disease Severity and Persistence in Pediatric Atopic Dermatitis
04/15/2026
Riya Gandhi, MA
Test your expertise in identifying risk factors for persistent pediatric atopic dermatitis and understanding the interplay between barrier dysfunction and immune dysregulation.
Test your expertise in identifying risk factors for persistent pediatric atopic dermatitis and understanding the interplay between barrier dysfunction and immune dysregulation.
Test your expertise in...
04/15/2026
The Dermatologist
Quiz
Type 2 Inflammation and Early Systemic Therapy in Pediatric Atopic Dermatitis
04/05/2026
Riya Gandhi, MA
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Assess advanced clinical...
04/05/2026
The Dermatologist
Quiz
Disease Heterogeneity in PN
03/15/2026
Riya Gandhi, MA
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of...
03/15/2026
The Dermatologist
Quiz
Rethinking Severity and JAK Inhibitor Strategy in Alopecia Areata
03/12/2026
Riya Gandhi, MA
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
How should clinicians redefine...
03/12/2026
The Dermatologist
Quiz
Cytokine Hierarchy and Sustained Pruritus in PN
03/10/2026
Riya Gandhi, MA
Explore the hierarchical and cooperative roles of IL-4, IL-13, and IL-31 in sustaining chronic itch and inflammation in prurigo nodularis.
Explore the hierarchical and cooperative roles of IL-4, IL-13, and IL-31 in sustaining chronic itch and inflammation in prurigo nodularis.
Explore the hierarchical and...
03/10/2026
The Dermatologist
Quiz
Type 2 Inflammation as a Pathogenic Driver in Prurigo Nodularis
03/05/2026
Riya Gandhi, MA
Test your understanding of how type 2 immune signaling drives chronic itch in prurigo nodularis through complex neuroimmune interactions.
Test your understanding of how type 2 immune signaling drives chronic itch in prurigo nodularis through complex neuroimmune interactions.
Test your understanding of how...
03/05/2026
The Dermatologist
psoriasis
Quiz
Distinguishing Feature of Generalized Pustular Psoriasis
03/02/2026
Jessica Garlewicz
What is a key distinguishing feature of generalized pustular psoriasis that differentiates it from plaque psoriasis?
What is a key distinguishing feature of generalized pustular psoriasis that differentiates it from plaque psoriasis?
What is a key distinguishing...
03/02/2026
The Dermatologist

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use